Chemours director Mary B Cranston acquires $94,950 in stock

Chemours director Mary B. Cranston purchased 6,000 shares of the company on August 7, 2026, for a total of $94,950. Following this purchase, her beneficial ownership in Chemours Co amounted to 113,140.9469 shares, including directly held shares, restricted stock units, and dividend equivalent units. This insider transaction occurred as Chemours stock experienced a 22% decline over the past six months, despite the company maintaining a 2.21% dividend yield.

The stock was deemed overvalued relative to its Fair Value by InvestingPro analysis. Investors can access comprehensive analysis through CC's Pro Research Report, part of the 1,400+ reports available on the platform. Chemours recently reported mixed second-quarter 2026 results, with earnings and sales falling short of Wall Street expectations.

UBS downgraded the company to Neutral, reducing its price target from $29.00 to $18.00, citing concerns about the earnings potential of Chemours' refrigerant business, TSS.